Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and (Nasdaq: BIIB, Corporate headquarters: Cambridge, ...

In October 2024, we provided updated results from our IMMUNOCERV Phase 2 clinical trial in locally advanced cervical cancer patients treated with Versamune ® HPV and chemoradiotherapy presented at the ...

Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data On track to dose first patient ...

AstraZeneca and Daiichi Sankyo have submitted a new Biologics License Application (BLA) for accelerated approval in the US ...

After a comprehensive two-year follow-up, researchers at the UCLA Health Jonsson Comprehensive Cancer Center found that ...

R&D expense for the third quarter of 2024 was $7.2 million, compared to $7.3 million for the third quarter of 2023. The decrease of $0.1 million was primarily due to lower clinical trial expenses ...

Expects to deliver three Investigational New Drug (IND) applications in next three years based on next-generation ADC technology -- Two new ...